Skip to main content
Premium Trial:

Request an Annual Quote

Gary Pace, David Gessner, Scott Clark, Susan Clark


Gentris has named Gary Pace vice president for corporate development, the company said Jan. 16. Pace, 49, comes to the pharmacogenomics company from stints at Allied-Signal, United AgiSeeds, Ciba-Geigey, and Novartis, where he was a patent attorney.

The company also promoted two staffers: David Gessner, 50, has been named vice president of business development, and Scott Clark, 36, was appointed executive director of laboratory services, Gentris said.


Epigenomics has named to its scientific advisory board: Johns Hopkins University professor Andrew Feinberg and Sydney Cancer Center associate professor Susan Clark.

Feinberg’s lab discovered CpG islands that are methylated in normal cells but are unmethylated in the diseased state. These will be used in Epigenomics’ marker-development pipeline.

Clark developed bisulfite sequencing, which helps detect methylation at any given cytosine in DNA. Subsequently, she discovered potentially useful diagnostic markers for the early detection of prostate cancer.

Filed under

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.